Sunnybrook Health Sciences Centre

About: Sunnybrook Health Sciences Centre is a healthcare organization based out in Toronto, Ontario, Canada. It is known for research contribution in the topics: Population & Breast cancer. The organization has 7689 authors who have published 15236 publications receiving 523019 citations. The organization is also known as: Sunnybrook.

1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence

Abstract: We hereby report a 1-year follow-up on eight women in the first North America trial in which stress urinary incontinence (SUI) was treated with muscle-derived stem cell injections. Mean and median follow-up in this group was 16.5 and 17 months (range 3–24 months). Improvement in SUI was seen in five of eight women, with one achieving total continence. Onset of improvement was between 3 and 8 months after injection. Cure or improvement continued at a median of 10 months. No serious adverse events were reported.

Functional Performance Measures: Are They Superior to Self-Assessments?

Abstract: BACKGROUND: It has been suggested that performance measures of functional status have several advantages over self-report measures for both clinical and research purposes, including: greater patient acceptability, interpretability, reproducibility, sensitivity to change, and the focus on actual ability rather than presumed capability. This article challenges this assumed superiority of "objective," "behavioral" measures by directly comparing self-assessments and blindly rated performance assessments on a specific item by task basis, using an identical rating format. METHODS: A set of 14 performance tasks, consisting of a range of functional abilities (including simulations of cooking and sweeping), was administered to 99 community-dwelling older adults (aged 60-92) who had previously completed a 50-item instrumental activities of daily living (IADL) questionnaire. A subsample was retested 2 weeks later, and reassessed at 1 year. RESULTS: Of 182 subjects willing and able to complete the IADL questionnaire, only 99 attempted at least one of the performance tasks. Tasks that took longer to complete were not necessarily associated with a greater number of errors, nor did accuracy ratings correspond well with difficulty ratings. Good correspondence (greater than 80% agreement) between observed and perceived difficulty was found for only one-third of the item/task matchings. Generally, the rater tended to underestimate difficulty relative to subjective assessments. CONCLUSIONS: Relative to questionnaires, performance measures were not found to be psychometrically superior, more acceptable to respondents, easier to administer, or easier to interpret. Neither type of measure by itself distinguishes between motivation and capability, reflects adaptations made in everyday living, or accounts for personal preferences or reasons for difficulty. Language: en

Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial

Abstract: It had been more than 5 years since the first case of Middle East Respiratory Syndrome coronavirus infection (MERS-CoV) was recorded, but no specific treatment has been investigated in randomized clinical trials. Results from in vitro and animal studies suggest that a combination of lopinavir/ritonavir and interferon-β1b (IFN-β1b) may be effective against MERS-CoV. The aim of this study is to investigate the efficacy of treatment with a combination of lopinavir/ritonavir and recombinant IFN-β1b provided with standard supportive care, compared to treatment with placebo provided with standard supportive care in patients with laboratory-confirmed MERS requiring hospital admission. The protocol is prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. Hospitalized adult patients with laboratory-confirmed MERS will be enrolled in this recursive, two-stage, group sequential, multicenter, placebo-controlled, double-blind randomized controlled trial. The trial is initially designed to include 2 two-stage components. The first two-stage component is designed to adjust sample size and determine futility stopping, but not efficacy stopping. The second two-stage component is designed to determine efficacy stopping and possibly readjustment of sample size. The primary outcome is 90-day mortality. This will be the first randomized controlled trial of a potential treatment for MERS. The study is sponsored by King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. Enrollment for this study began in November 2016, and has enrolled thirteen patients as of Jan 24-2018. ClinicalTrials.gov, ID: NCT02845843. Registered on 27 July 2016.

Effects at Two Years of a Low-Fat, High-Carbohydrate Diet on Radiologic Features of the Breast: Results From a Randomized Trial

Abstract: Background: The appearance of breast tissue on mammography varies according to its composition. Fat is radiolucent and appears dark on mammography, while stromal and epithelial tissue has greater optical density and appears light. Extensive areas of radiologically dense breast tissue seen on mammography are associated with an increased risk of breast cancer. Purpose: The purpose of the present study was to determine whether the adoption of a low-fat, high-carbohydrate diet for 2 years would reduce breast density. Methods: Women with radiologic densities in more than 50% of the breast area on mammography were recruited and randomly allocated to an intervention group taught to reduce intake of dietary fat (mean, 21% of calories) and increase complex carbohydrate (mean, 61% of calories) or to a control group (mean, 32% of calories from fat and 50% of calories from carbohydrates). Mammographic images from 817 subjects were taken at baseline and compared with those taken 2 years after random allocation by use of a quantitative image analysis system, without knowledge of the dietary group of the subjects or of the sequence in which pairs of images had been taken. The effects of the intervention on the mammographic features of breast area, area of dense tissues in the breast, and the percent of the breast occupied by dense tissue were examined using t tests. Multiple regression was used to examine these effects while accounting for age at trial entry, weight change, and menopausal status. Results: After 2 years, the total area of the breast was reduced by an average of 233.7 mm 2 (2.4%) (95% confidence interval [CI] = 106.9-360.6) in the intervention group compared with an average increase of 26.3 mm 2 (0.3%) (95% CI = -108.0-160.5) in the control group (P = .01). The area of density was reduced by 374.4 mm 2 (6.1%) (95% CI = 235.1-513.8) in the intervention group compared with an average of 127.7 mm 2 (2.1%) (95% CI = 8.6-246.7) in the control group (P = .01). Weight loss was associated with a reduction in breast area. The effect of the intervention on breast area was only marginally statistically significant after weight change, menopausal status, and age at trial entry were taken into account (P = .06). Greater weight loss and becoming postmenopausal were associated with statistically significant reductions in the area of density on the mammographic image at 2 years (P = .04 and P<.001, respectively). Age at entry into the trial was marginally significant in the same direction (P =.06). The effect of the intervention on area of density remained statistically significant after controlling for weight loss, age at entry, and menopausal status (P =.03). The change in the percentage of dense tissue in the mammographic image was not significantly different between the two groups (P =.71). Conclusions and Implications: These results show that after 2 years, a low-fat, high-carbohydrate diet reduced the area of mammographic density, a radiographic feature of the breast that is a risk factor for breast cancer. Longer observation of a larger number of subjects will be required to determine whether these effects are associated with changes in risk of breast cancer.